Navigation Links
Scleroderma Cure Still In Oscillation

According to a recent study, an old drug promises to slow down the progress of the dreadful autoimmune disease scleroderma or systemic sclerosis//.

About 3,00,000 Americans were found to be affected by the fatal disease Scleroderma, which destroys our system by hardening and thickening the skin and in many times it completely damages the lungs and other related organs. Nearly 80% of affected people have lung damaged more often it includes women only.

When comparing the benefits with after effects of a usual drug named cyclophosphamide, or Cytoxan, used to treat cancer and some autoimmune disorders, only minimum benefits were evidenced.

The study authors reported that 158 scleroderma patients from the country’s hospital were assigned at random into 2 groups, which includes experimental group (taking Cytoxan pills) and control group (taking only dummy pills) 1 per day for a period of 1 year. Throughout the year they were monitered, and the results show only a little improvement in using Cytoxan group of drugs although there seems a statistically significant difference – said Dr. Philip J. Clements, a rheumatologist at the University of California, Los Angeles, who was a co-author of the study.

One among the adverse effects of using Cytoxan group of drugs was low white blood cell count, says author.

Dr. Clements reported in an interview that beyond many studies Cytoxan with little side effects for scleroderma patients only proves in part to benefit scleroderma patients with lung damage.

Since having adverse effects in the long-term use of the drug, researchers urged to carry out a follow up of this study in a fast rate.


'"/>




Page: 1

Related medicine news :

1. Cancer Drug to Treat Scleroderma Lung Disease
2. Link between C-section Delivery and Stillbirth
3. Estimates For Number Of HIV/AIDS Deaths In India Still Not Available
4. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
5. Past President Narayanans Condition Still Critical
6. LASIK Treatments Still To Reach Common Man
7. Hurricane Hangover: Katrina Still Haunts
8. Tuberculosis Is Still A Major Health Threat In Africa
9. Despite More Studies Researchers Are Still Confound With ADHD
10. Children Are Exercising Much Harder, But Are Still Obese
11. Study Shows That More Than 3 Million Stillbirths Occur Worldwide Every Year
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: